Advanced Non-Small Cell Lung Cancer
Conditions
Interventions
Consolidative Radiotherapy or Thermal Ablation group:Consolidative Radiotherapy or Thermal Ablation
Sponsors
Xiaolan People's Hospital of Zhongshan City
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients with histologically confirmed advanced NSCLC harboring sensitive EGFR mutations (exon 19 deletion or exon 21 L858R mutation), with no restrictions on the number, location, or size of metastatic lesions (including both oligometastases and multiple metastases). 2.Have not previously received EGFR-TKIs or immune checkpoint inhibitors; 3.No history of interstitial lung disease; 4.Basic functional status of vital organs is essentially normal. 5.Aged >= 18 years; 6.Signed informed consent form;
Exclusion criteria
Exclusion criteria: 1.Patients currently receiving other effective treatments; 2.Refractory nausea and vomiting, chronic gastrointestinal diseases, or inability to swallow medication, which may affect the ingestion, transit, or absorption of the drug. 3.Patients with severe concomitant diseases or any other conditions deemed by the investigator to make the patient unsuitable for participation in this study. 4.Patients who have not undergone regular efficacy and safety assessments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Duration of almonertinib treatment;Treatment-related adverse events; | — |
Countries
China
Contacts
Public ContactXin Li
Xiaolan People's Hospital of Zhongshan City
Outcome results
None listed